Darzalex Faspro-Based Quadruplet Regimen Approved for Newly Diagnosed Patients with Multiple Myeloma who are Transplant Ineligible

Jan 28, 2026 - 14:00
 0  0
HORSHAM, Pa., January 27, 2026 – Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0